Загрузка...
Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
PURPOSE: The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as a single agent and in combination 13-cis retinoic acid (13cRA) in children with refractory solid tumors; to evaluate the tolerabili...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Clinical Oncology
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2917318/ https://ncbi.nlm.nih.gov/pubmed/20606092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.9119 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|